Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide for the regulation of therapeutic goods in Australia, ensuring that such goods are of acceptable quality and safe for use. This Act was introduced to address the need for a cohesive regulatory framework governing the importation, supply, and quality of therapeutic goods, thus ensuring public health and safety. The Act is administered by the Therapeutic Goods Administration, which operates under the auspices of the Department of Health. The policy objective underlying the Act is to safeguard the health and safety of Australians by ensuring that therapeutic goods meet the required standards. Recently, on 5 May 2015, the delegate of the Secretary of the Department of Health issued a consent under sections 14 and 14A of the Act, allowing the importation and supply of rizatriptan (as benzoate) (RIZATRIPTAN WAFERS) 10 mg wafer blister pack [AUST R 225969] despite non-compliance with certain labelling requirements. This consent, effective until 30 May 2016, was granted with specific conditions to mitigate any potential risks associated with the non-conformity of the product's labelling.

Scope and Application

The Therapeutic Goods Act 1989, as amended and administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia’s Department of Health, governs the regulation of therapeutic goods in Australia. This includes medicines, medical devices, blood and tissues, and cosmetics. The Act applies to persons and entities involved in the importation, manufacture, supply, and advertising of therapeutic goods within Australia. It establishes standards and controls to ensure that therapeutic goods are safe, of high quality, and perform as claimed. The Act applies across the entire Commonwealth, including all states and territories, ensuring a uniform regulatory approach. Certain classes of goods, such as those considered low-risk, may be exempt from some regulatory requirements, and thresholds may apply to determine the level of scrutiny necessary. The Act's provisions can be extended or refined through subordinate instruments, such as therapeutic goods orders, which provide more detailed specifications and standards. In the case of the consent granted to Merck Sharp & Dohme Australia Pty Ltd for the importation and supply of rizatriptan, the Act allows for specific exemptions from labelling requirements under particular conditions, ensuring that the therapeutic goods remain safe and effective while accommodating certain practical considerations.

Key Provisions

The main operative sections of this legislation are sections 14 and 14A of the Therapeutic Goods Act 1989. Section 14 allows for consent to be given for the importation and supply of therapeutic goods that do not conform to certain legislative requirements, while section 14A allows for such consent to be subject to specific conditions. In this instance, section 14(1) has been utilised to permit the importation and supply of rizatriptan (as benzoate) (RIZATRIPTAN WAFERS) 10 mg wafer blister pack [AUST R 225969], which does not conform to the requirements of the Therapeutic Goods Order No. 69, specifically paragraph 3(12)(a) relating to label information. The consent given under section 14A(1) also imposes conditions on this consent, which must be adhered to by the party granted the consent. The Therapeutic Goods Act 1989 imposes specific obligations and requirements on entities involved in the importation and supply of therapeutic goods. These obligations include ensuring that therapeutic goods meet the necessary standards for safety, quality, and efficacy as stipulated in the Act and relevant Therapeutic Goods Orders. In this case, the Act requires that the blister foil label for medicines must include the name or registered trademark of the sponsor and the product name of the medicine. However, the consent granted under section 14 of the Act allows for an exemption to this requirement, subject to the conditions imposed. Failure to comply with the conditions of the consent granted under section 14A of the Therapeutic Goods Act 1989 may result in legal consequences. The Act does not specify the exact penalties for non-compliance, but it is likely that any breach of the conditions would be considered a contravention of the Act, potentially leading to fines, legal action, or other enforcement measures as deemed appropriate by the Department of Health. It is crucial for the party granted the consent, Merck Sharp & Dohme Australia Pty Ltd, to strictly adhere to the conditions imposed to avoid any potential legal repercussions.